200 related articles for article (PubMed ID: 18561322)
1. Nuclear karyopherin alpha2 expression predicts poor survival in patients with advanced breast cancer irrespective of treatment intensity.
Gluz O; Wild P; Meiler R; Diallo-Danebrock R; Ting E; Mohrmann S; Schuett G; Dahl E; Fuchs T; Herr A; Gaumann A; Frick M; Poremba C; Nitz UA; Hartmann A
Int J Cancer; 2008 Sep; 123(6):1433-8. PubMed ID: 18561322
[TBL] [Abstract][Full Text] [Related]
2. Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial.
Erber R; Gluz O; Brünner N; Kreipe HH; Pelz E; Kates R; Bartels A; Huober J; Mohrmann S; Moustafa Z; Liedtke C; Möbus V; Augustin D; Thomssen C; Jänicke F; Kiechle M; Kuhn W; Nitz U; Harbeck N; Hartmann A
Breast Cancer Res Treat; 2015 Apr; 150(2):279-88. PubMed ID: 25721604
[TBL] [Abstract][Full Text] [Related]
3. Karyopherin alpha 2 is a novel prognostic marker and a potential therapeutic target for colon cancer.
Zhang Y; Zhang M; Yu F; Lu S; Sun H; Tang H; Peng Z
J Exp Clin Cancer Res; 2015 Dec; 34():145. PubMed ID: 26626145
[TBL] [Abstract][Full Text] [Related]
4. Nuclear karyopherin-α2 expression in primary lesions and metastatic lymph nodes was associated with poor prognosis and progression in gastric cancer.
Altan B; Yokobori T; Mochiki E; Ohno T; Ogata K; Ogawa A; Yanai M; Kobayashi T; Luvsandagva B; Asao T; Kuwano H
Carcinogenesis; 2013 Oct; 34(10):2314-21. PubMed ID: 23749771
[TBL] [Abstract][Full Text] [Related]
5. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial.
Gluz O; Nitz UA; Harbeck N; Ting E; Kates R; Herr A; Lindemann W; Jackisch C; Berdel WE; Kirchner H; Metzner B; Werner F; Schütt G; Frick M; Poremba C; Diallo-Danebrock R; Mohrmann S;
Ann Oncol; 2008 May; 19(5):861-70. PubMed ID: 18174609
[TBL] [Abstract][Full Text] [Related]
6. KPNA2 protein expression in invasive breast carcinoma and matched peritumoral ductal carcinoma in situ.
Dankof A; Fritzsche FR; Dahl E; Pahl S; Wild P; Dietel M; Hartmann A; Kristiansen G
Virchows Arch; 2007 Nov; 451(5):877-81. PubMed ID: 17899179
[TBL] [Abstract][Full Text] [Related]
7. Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer.
Dahl E; Kristiansen G; Gottlob K; Klaman I; Ebner E; Hinzmann B; Hermann K; Pilarsky C; Dürst M; Klinkhammer-Schalke M; Blaszyk H; Knuechel R; Hartmann A; Rosenthal A; Wild PJ
Clin Cancer Res; 2006 Jul; 12(13):3950-60. PubMed ID: 16818692
[TBL] [Abstract][Full Text] [Related]
8. Low cytoplasmic and nuclear KPNA2 expression in radiotherapy-treated head and neck squamous cell cancer is associated with an adverse outcome.
Erben PB; Brunner K; Hecht M; Haderlein M; Büttner-Herold M; Agaimy A; Fietkau R; Hartmann A; Distel LV
Int J Clin Exp Pathol; 2015; 8(12):15814-24. PubMed ID: 26884852
[TBL] [Abstract][Full Text] [Related]
9. Significance of karyopherin-{alpha} 2 (KPNA2) expression in esophageal squamous cell carcinoma.
Sakai M; Sohda M; Miyazaki T; Suzuki S; Sano A; Tanaka N; Inose T; Nakajima M; Kato H; Kuwano H
Anticancer Res; 2010 Mar; 30(3):851-6. PubMed ID: 20393006
[TBL] [Abstract][Full Text] [Related]
10. KPNA2 over-expression is a potential marker of prognosis and therapeutic sensitivity in colorectal cancer patients.
Takada T; Tsutsumi S; Takahashi R; Ohsone K; Tatsuki H; Suto T; Kato T; Fujii T; Yokobori T; Kuwano H
J Surg Oncol; 2016 Feb; 113(2):213-7. PubMed ID: 26663089
[TBL] [Abstract][Full Text] [Related]
11. Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trial.
Gluz O; Wild P; Liedtke C; Kates R; Mendrik H; Ehm E; Artinger V; Diallo-Danebrock R; Ting E; Mohrmann S; Poremba C; Harbeck N; Nitz U; Hartmann A; Gaumann A
Breast Cancer Res Treat; 2011 Apr; 126(3):643-51. PubMed ID: 21318601
[TBL] [Abstract][Full Text] [Related]
12. Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.
Razis E; Kalogeras KT; Kotoula V; Eleftheraki AG; Nikitas N; Kronenwett R; Timotheadou E; Christodoulou C; Pectasides D; Gogas H; Wirtz RM; Makatsoris T; Bafaloukos D; Aravantinos G; Televantou D; Pavlidis N; Fountzilas G
Clin Breast Cancer; 2012 Jun; 12(3):183-93. PubMed ID: 22607768
[TBL] [Abstract][Full Text] [Related]
13. KPNA2 predicts long term survival in patients with anaplastic oligoastrocytomas.
Gousias K; Niehusmann P; Gielen G; Simon M; Boström J
J Clin Neurosci; 2014 Oct; 21(10):1719-24. PubMed ID: 24929863
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
[TBL] [Abstract][Full Text] [Related]
15. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
[TBL] [Abstract][Full Text] [Related]
16. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A;
Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514
[TBL] [Abstract][Full Text] [Related]
17. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
[TBL] [Abstract][Full Text] [Related]
18. Nuclear transport receptor karyopherin-α2 promotes malignant breast cancer phenotypes in vitro.
Noetzel E; Rose M; Bornemann J; Gajewski M; Knüchel R; Dahl E
Oncogene; 2012 Apr; 31(16):2101-14. PubMed ID: 21909132
[TBL] [Abstract][Full Text] [Related]
19. Obesity as an independent risk factor for decreased survival in node-positive high-risk breast cancer.
Scholz C; Andergassen U; Hepp P; Schindlbeck C; Friedl TW; Harbeck N; Kiechle M; Sommer H; Hauner H; Friese K; Rack B; Janni W
Breast Cancer Res Treat; 2015 Jun; 151(3):569-76. PubMed ID: 25962694
[TBL] [Abstract][Full Text] [Related]
20. TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.
Kassem L; Deygas M; Fattet L; Lopez J; Goulvent T; Lavergne E; Chabaud S; Carrabin N; Chopin N; Bachelot T; Gillet G; Treilleux I; Rimokh R
BMC Cancer; 2015 Jun; 15():453. PubMed ID: 26040677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
